Despite a high degree of conservation, subtle but important differences exist between the CD1d antigen presentation pathways of humans and mice. These differences may account for the minimal success of natural killer T (NKT) cell-based antitumor therapies in human clinical trials, which contrast strongly with the powerful antitumor effects in conventional mouse models. To develop an accurate model for in vivo human CD1d (hCD1d) antigen presentation, we have generated a hCD1d knock-in (hCD1d-KI) mouse. In these mice, hCD1d is expressed in a native tissue distribution pattern and supports NKT cell development. Reduced numbers of invariant NKT (iNKT) cells were observed, but at an abundance comparable to that in most normal humans. These iNKT cells predominantly expressed mouse Vβ8, the homolog of human Vβ11, and phenotypically resembled human iNKT cells in their reduced expression of CD4. Importantly, iNKT cells in hCD1d knock-in mice exert a potent antitumor function in a melanoma challenge model. Our results show that replacement of mCD1d by hCD1d can select a population of functional iNKT cells closely resembling human iNKT cells. These hCD1d knock-in mice will allow more accurate in vivo modeling of human iNKT cell responses and will facilitate the preclinical assessment of iNKT cell-targeted antitumor therapies.
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humanized mouse | immunotherapy | antitumor immunity T ype 1 or invariant natural killer T (iNKT) cells are among the first responders during many types of immune responses and play critical immunomodulatory functions in diverse immunologic, infectious, and neoplastic diseases (1) . The key molecule involved in the thymic selection, development, and immune recognition by iNKT cells is CD1d, a nonpolymorphic MHC I-like surface glycoprotein (1) . The human CD1d (hCD1d) and mouse CD1d (mCD1d) proteins are largely conserved in amino acid sequence and 3D structure (1, 2) . However, many subtle but important differences exist between hCD1d and mCD1d, including differences in their affinities for various lipid ligands and iNKT cell T cell receptors (TCRs) (2, 3) , as well as clearly delineated differences in 3D structures (4) and intracellular trafficking properties (5, 6) . On the other hand, iNKT cells in the human and mouse have several notable differences, particularly in their relative abundance among lymphocyte subpopulations (7) and their expression of phenotypic markers (1, 8) .
Evidence for iNKT cell functions in antitumor immunity initially came from studies in mice of the potent antitumor activity of α-galactosylceramide (α-GalCer), a marine sponge-derived glycolipid that activates most iNKT cells (9) . Extensive studies from many groups have substantiated this protective role of iNKT cells against tumors in mice (10, 11) . Several phase-I exploratory trials of the anticancer activity of α-GalCer in humans have been reported (reviewed in ref. 12 ), but these have not shown consistent therapeutic benefit. The sharp discrepancy between the results obtained in tumor-bearing mice and human cancer patients treated with α-GalCer may be related to the differences between human and mouse CD1d molecules, and related differences in CD1d-restricted iNKT cells. In particular, the much greater abundance of iNKT cells in mice compared with humans has been considered to be a major flaw with conventional mouse models, limiting their predictive utility for humans. However, data for in vivo human CD1d lipid presentation are sparse and originate from a very limited number of human patients. To establish a small animal model for in vivo study of human CD1d presentation of lipids to NKT cells, we report an hCD1d knock-in (hCD1d-KI) mouse that provides a unique model that more accurately replicates features of iNKT cell responses in humans.
Results and Discussion
Generation of hCD1d Knock-in Mice and Their hCD1d Expression in Vivo. In previously reported hCD1d transgenic models, the expression of hCD1d is either restricted to thymocytes or dendritic cells (13) or widely expressed in all nucleated cells (14) . To mimic the natural CD1d expression pattern, we generated mice in which hCD1d was expressed under control of the endogenous mCD1d promoter and regulatory elements. The promoter regions of hCD1D and mCD1D genes have homologous sequences containing putative binding sites for at least some transcriptional factors (15, 16) . However, to ensure the compatibility with mouse transcriptional factors and proper temporal and spatial expression of hCD1d in the mouse, we generated a gene targeting construct in which a human genomic fragment containing all six exons of the human CD1D gene was fused to mouse genomic fragments flanking the mouse CD1D1 coding region (Fig. 1A) . In mice, there are two CD1D genes, designated CD1D1 and CD1D2 (1) . Whereas CD1D1 has been found to play the major role in NKT cell development and function, the function of CD1D2 is unclear, but it is expressed at the cell surface of thymocytes in some mouse strains including CD1D1-deficient mice derived from 129 embryonic stem (ES) cells used in most gene targeting (17) . However, CD1D2 is a pseudogene in the C57BL/6 strain (18). We therefore used ES cells of this strain for gene targeting to replace mouse CD1D1 with the human CD1D sequence (Fig.  1A) . This ensured that hCD1d is the only restricting molecule for NKT development and function in the resulting animals.
The precise homologous recombination and integration of the human genomic CD1D gene in the mouse CD1D1 locus was verified by long-range PCR (Fig. 1B) . The entire genomic region encompassing the 5′ and 3′ flanking mouse genomic fragments and the human CD1D gene was sequenced, excluding undesired mutation or recombination events. Mosaic mice with germ-line transmission of the ES cell-derived human CD1D gene were crossed to C57BL/6 mice and then intercrossed to obtain homologous KI mice. Human and mouse CD1D-specific primers were used to genotype the KI mice (Fig. 1C) . To confirm the hCD1d protein expression, thymocytes from WT C57BL/6, heterozygous and homozygous KI mice were subjected to flow cytometry using mCD1d-and hCD1d-specific monoclonal antibodies. As expected, only hCD1d was expressed in homozygous KI mice, whereas expression of both hCD1d and mCD1d proteins could be detected in the heterozygotes at lower levels (Fig.  1D) . To survey the tissue expression of hCD1d, we performed RT-PCR with hCD1D-specific primers. Expression of human CD1D transcripts was detected at varying levels in all tissues examined, consistent with the widespread transcription within hematopoietic lineages and low-level expression that has been reported in several types of epithelia (1) . Notably, this expression pattern was similar to that of endogenous mCD1D transcripts in WT mice (Fig. 1E ).
Efficient Presentation of Lipid Ligands by hCD1d in KI Mice. To examine the lipid-presenting function of hCD1d in the KI mice, we assayed the ability of bone marrow-derived dendritic cells (BMDCs) derived from KI mice to stimulate in vitro responses of mouse iNKT cell hybridomas to the well-characterized synthetic glycolipid α-GalCer. As expected, hCD1d expression was detected on the surface of BMDCs from hCD1d-KI but not from WT mice ( Fig. 2A) . Presentation of α-GalCer by BMDCs from KI mice was potent and generated responses of similar magnitude compared with presentation by WT BMDCs. The specificity of the responses was confirmed by blocking with species-specific mAbs reactive with mCD1d or hCD1d (Fig. 2B) . We also observed that freshly harvested thymocytes from hCD1d-KI mice presented α-GalCer to iNKT cell hybridomas in an hCD1d-specific fashion (Fig. S1A) , suggesting hCD1d molecules can present endogenous lipids for iNKT cell development in the KI mice.
One prominent difference that has been documented between human and mouse CD1d proteins is in their patterns of intracellular trafficking and localization. This is believed to be mainly due to a much stronger interaction of mCD1d compared with hCD1d with the clathrin adaptor protein AP-3, which routes the protein into late endosomes and lysosomes (5, 6) . This interaction is required for normal iNKT cell development in mice, as well as for efficient lipid presentation of complex glycolipid antigens that require enzymatic processing in the late endosomal or lysosomal compartments (6) . To examine whether hCD1d can present such complex glycolipid antigens in KI mice, we performed lipid presentation with Gal(α1→2)α−GalCer, a complex glycolipid that must be processed by the lysosomal enzyme α-galactosidase A to be recognized by iNKT TCRs (19) . We indeed detected efficient presentation of the complex glycolipid to iNKT cell hybridomas (Fig. 2C Upper) . To verify that this presentation is mediated by internationalization and processing of Gal(α1→2)α-GalCer, we fixed the BMDCs by paraformaldehyde before lipid loading and presentation. Whereas the α-GalCer could still be presented, presumably through direct loading to surface hCD1d molecules (Fig. 2C Lower) , the presentation of Gal(α1→2)α-GalCer was completely abolished (Fig. 2C Upper) . To examine whether hCD1d in the KI mice can present glycolipids to human iNKT cells, we performed lipid presentation assay using a human CD4+ iNKT cell line, 6F5 (20) , and detected efficient presentation of both α-GalCer and Gal-α-GalCer to human NKT cells (Fig. S1B ). Together efficient and apparent endocytosis-dependent presentation of the complex glycolipid by KI BMDC suggest that hCD1d was able to traffic into late endosomal or lysosomal compartments and access the complex glycolipids, indicating a positive interaction between hCD1d and the mouse AP-3 complex.
Development of Human-Like NKT Cell Populations in hCD1d-KI Mice.
Initial studies of general immune system development in hCD1d-KI mice showed no gross abnormalities in total cellularity or in lymphocyte subsets, and the mice developed and gained weight normally ( Fig. S1 C-F) . These results were consistent with earlier reports in CD1d −/− and hCD1d transgenic mice and indicate that ablation or alteration in CD1d expression does not significantly affect the development of conventional T, B, and dendritic cells (13, 14, 21) . However, not surprisingly, we detected significant differences in NKT cell development in hCD1d-KI mice. First, there is a marked reduction in NK1.1 + TCRβ + cells in major immune organs in the KI mice. For example, there were ∼6% of the total liver mononuclear cells in hCD1d-KI mice (Fig. 3A  Upper) , compared with ∼20% in WT mice (1) . In CD1d −/− mice, we detected average ∼5% NK1.1
+

TCRβ
+ cells, which have been previously characterized as non-CD1d-restricted NKT-like T cells (22) . Staining with α-GalCer loaded mCD1d tetramers showed that almost none of these NK1.1 + TCRβ + cells were α-GalCerreactive iNKT cells in CD1d −/− mice, whereas the great majority of them were tetramer-positive in WT mice. In contrast, a smaller but substantial fraction of NK1.1 + TCRβ + cells in hCD1d-KI mice (∼27%) were tetramer-positive, most likely representing hCD1d-restricted iNKT cells (Fig. 3B) With α-GalCer-loaded mCD1d tetramers, we clearly detected a distinct population of TCRβ + tetramer + iNKT cells in thymus, liver, and spleen of hCD1d-KI mice (Fig. 3C) . Similar results were obtained with α-GalCer-loaded hCD1d tetramer (Fig.  S1G ). These cells expressed promyelocytic leukemia zinc finger, a key transcription factor directing the development of iNKT cells and other innate T cells (25) (Fig. 3D ). These observations indicated that hCD1d efficiently presents endogenous lipid antigens to support the development of iNKT cells in the thymus, as well as maintaining in vivo homeostasis and survival of iNKT cells in periphery of hCD1d-KI mice. The abundance of iNKT cells in the thymus was ∼10% of that in WT mice (Fig.  3C) , which is similar to what has been reported in hCD1d transgenic models (13) . The much lower abundance in the thymus is most likely due to a lower iNKT cell developmental output when their thymic selection is restricted by hCD1d as opposed to mCD1d. The reason for this is not yet clear, because with the endogenous mouse CD1d promoter, the precise spatial and temporal expression and levels of hCD1d during thymic development are expected to be comparable to that of native mouse CD1d in WT mice. This suggests that an intrinsic property of the hCD1d protein is responsible for the reduced thymic output of iNKT cells in hCD1d-KI mice, which occurs similarly in humans (26) . One well-documented difference between human and mouse CD1d molecules is the substantially lower affinity of hCD1d-lipid complex to NKT TCRs (2). It will be intriguing to further study how this lower affinity can potentially lead to lower NKT cell development. However, the lower abundance of iNKT cells in peripheral tissues is a function of both the thymic output of nascent iNKT cells and the homeostatic control of mature iNKT cells (1) . Importantly, the abundance of iNKT cells in all tissues examined in our KI mice is comparable to that in humans, making up ∼1-2% of liver mononuclear cells and a substantially smaller fraction of splenocytes (7, 27) . This indicates that our hCD1d-KI mouse will be a proper model to study the in vivo functionality of iNKT cells at an abundance similar to that found in most normal humans.
Mouse iNKT cells have limited TCR diversity, expressing an invariant TCRα chain (Vα14Jα18) paired with limited TCRβ chains (Vβ8, Vβ7, and Vβ2) (1). In hCD1d-KI mice, we detected significantly increased Vβ8 use (over 80% of all iNKT cells) in comparison with WT mice (∼50% of iNKT cells) with correspondingly lower Vβ7 use (reduced from about 13 to 7% in iNKT cells) (Fig. 3E) . In WT mice, the remaining fraction of iNKT cells (∼35%) expresses Vβ2 and other Vβ chains, whereas in hCD1d-KI mice, this fraction accounts for only ∼9% of all iNKT cells. Vβ8 is the closest homolog to Vβ11 in human (2), the sole Vβ chain paired with the invariant TCRα chains (Vα24Jα18) in human iNKT cell TCRs (1). It is therefore reasonable to expect that Vβ8 would have greater structural compatibility with hCD1d, as suggested by the much higher affinity of hCD1d/ α-GalCer complexes to mouse iNKT cell TCRs containing Vβ8 compared with those containing Vβ7 (2) . This relatively high affinity may allow more efficient positive selection of Vβ8 iNKT cells during the iNKT development. Analysis of CD4 expression by iNKT cells in hCD1d-KI mice showed a substantially lower fraction of CD4+ iNKT cells and a higher fraction with double negative (DN) phenotype in liver and spleen compared with WT mice (Fig. 3F) . In the thymus of hCD1d-KI mice, more than half of iNKT cells were DN, also a clear increase compared with WT mice (Fig. 3F) . Interestingly, the CD4+/DN ratio for iNKT cells in hCD1d-KI mice was similar to that reported in humans, both in peripheral blood and in the liver (7, 28) . These findings suggest that hCD1d-KI mice may be useful as a model to study the development of the CD4 phenotype of human iNKT cells, and for assessing the proliferative potential of mature CD4+ versus DN iNKT cells in peripheral tissues (29) .
Potent Inhibition of Tumor Metastasis by iNKT Cells in hCD1d-KI Mice.
To investigate the functionality of iNKT cells in hCD1d-KI mice, we first demonstrated the presence of mRNA transcripts for IFN-γ and IL-4 in sorted peripheral CD1d tetramer+ iNKT cells (Fig. S2A) . We then performed in vitro stimulation of iNKT cells with PMA and ionomycin and confirmed their secretion of IFN-γ and IL-4 (Fig. S2B) . To examine the in vivo response of iNKT cells to lipid ligands, we administrated α-GalCer into the KI mice and examined cytokine secretion. Given the lower numbers of iNKT cells in hCD1d-KI mice, we expected a lower cytokine yield and therefore used a sensitive FACS-based cytokine detection assay. This demonstrated low levels of IFN-γ at 2 h, which increased at 12 h posttreatment. A detectable amount of , and hCD1d-KI strains were prepared and subjected to NK1.1, TCRβ, and α-GalCer-loaded mCD1d tetramer staining. In A, gated NK1. IL-4 was also present at 2 h posttreatment but diminished to background levels at 12 h (Fig. 4A) . The temporal pattern of cytokine secretion was thus very similar to that observed in WT mice, although the absolute amounts of both IFN-γ and IL-4 were substantially lower (Figs. 4A and S2C ).
To investigate whether iNKT cells in hCD1d-KI mice were functional in antitumor immunity, we established a B16 melanoma model in the KI mice. Congenic B16 melanoma cells were injected i.v. into KI mice, and lung metastases were enumerated 2 wk later. We administrated α-GalCer 2 d before the B16 cell injection, a well-established procedure for demonstrating antitumor function of mouse iNKT cells (30) . Although a trend toward inhibition of B16 metastasis in the lung after α-GalCer administration was observed, this did not achieve statistical significance (Fig. S2D) . To enhance the lipid presentation efficiency, we loaded autologous BMDCs from KI mice with α-GalCer and administrated these into the KI mice, a procedure reported to prolong iNKT cell responses (31) . Using this approach, B16 metastasis was significantly inhibited by α-GalCer administration in hCD1d-KI mice (Fig. 4 B-D) . Histologic studies showed typical metastatic B16 tumors in the lungs, with fewer metastases in the samples from α-GalCer-loaded BMDC-treated mice (Fig. 4C) .
In summary, we have successfully generated a hCD1d-KI mouse and shown that they develop functional hCD1d-restricted iNKT cells with striking similarities to those of humans in frequency and phenotype. We also provided in vivo evidence that hCD1d can present lipids to stimulate NKT cells for anti-tumor function. Our hCD1d-KI mice thus represent a unique humanized mouse model that paves the way for further in-depth study of in vivo hCD1d lipid presentation and the identification of unique iNKT cell ligands targeting cancer and other immune diseases.
Materials and Methods
Mice. C57BL/6 mice were purchased from the Jackson Laboratory and bred locally. C57BL/6 background CD1d −/− mice were generously provided by Chyung-Ru Wang, Northwestern University, Evanston, IL. All animal procedures were approved by the Institutional Animal Care and Use Committee at the University of Southern California.
Generation of hCD1d Knock-in Mice. The bacterial artificial chromosome clones encoding human and mouse CD1d genomic regions were obtained from BACPC Resources Center, Children's Hospital Oakland Research Institute, Oakland, CA. PCR was used to generate a construct encompassing the hCD1d genomic region flanked by the 5′ and 3′ regions of mouse CD1d1 genomic regions. The primers ATGGGGTGCCTGCTGTTTCTGCTG and CTCTCACAGTTCCTATCAGGGCGTCCTGTGA were used to amplify the hCD1D genomic fragment corresponding to human chromosome 1 nucleotide 3257291-3254243 (NCBI reference sequence NW_001838531.2). For mouse CD1D1 genomic fragments, 5′ end primers GTCCTGATATCTTGTCTTCCA-TTTGATCCATTTTTCATGTATGCC and AGCGCCAGAGTTCTACACAGCCCTC-GGCTCC and 3′ end primers GCAGGAGAGGCAGGTGTAAGGAAGAG and AGGCTAGCCTCAGGCCTCCTTCTGTCTTACCTTCCC were used to amplify the 5′ and 3′ end of mouse genomic regions, respectively. The 5′ and 3′ end fragments have sequences corresponding to mouse chromosome 3 nucleotides 36185528-36190527 and 36179808-36182854, respectively (both in NCBI reference sequence NT_039240.8). The construct was generated in pEZFRTloxDT vector generously provided by Dominik Schenten (Yale University School of Medicine, New Haven, CT) and Klaus Rajewsky (Harvard Medical School, Boston, MA). Strain C57BL/6-derived embryonic stem cells were electroporated with linearized genomic DNA construct and embryonic stem cell clones were selected for G418 resistance and screened for human genomic DNA insertion by PCR. Sequence-specific primers were used to amplify the 5′, central, and 3′ end genomic fragments. The entire genomic mCD1d region with recombined human genomic region encoding hCD1d was sequenced. Neomycin-resistant ES clones were injected into mouse blastocysts to produce chimeric mice, and germ-line transmission of the human genomic DNA was verified by PCR analysis of tail DNA. In the gene-targeting construct, neomycin-resistance (NeoR) gene was flanked by yeast flippase recognition target sites. The founder mouse with ES cell-derived germ-line transmission of the hCD1D gene was further bred to flippase-transgenic mice to remove the NeoR gene. Further intercrossing was performed to obtain homozygous mice containing the hCD1D gene. Genotyping was done using mCD1D and hCD1D-specific primers to amplify genomic sequences from tail fragments to verify the presence of hCD1D and absence of mCD1D1 gene in the mice. Flow Cytometry and Intracellular Cytokine Staining. Single-cell suspensions were prepared from thymus, spleen, and liver in FACS staining buffer (0.5% BSA, 0.09% sodium azide) and red blood cells were removed using RBC lysis buffer (BioLegend). Cells were incubated with anti-CD16/32 to block FcγRII/III, followed by staining with fluorochrome-conjugated mAbs for mouse antigens, including FITC-mCD1d (1B1), PE-mCD1d (1B1), PerCPcy5.5-TCRb (H57-597), Alexa647-TCR Vβ8.1,8.2 (KJ16-133.18), Alexa647-TCR Vβ2 (B20.6), FITC-TCR Vβ7 (TR310), eF450-NK1.1 (PK136), PEcy7-CD4 (GK1.5), APCeF780-CD8α (53-6.7), PE-mCD1d/PBS-57 tetramer or PE-hCD1d/PBS-57 tetramer (NIH Tetramer Core Facility, Emory University, Atlanta, GA), purified mouse antihuman CD1d (CD1d51), APC-CD19 (1D3), eF450-CD11c (N148), PerCPcy5.5- IFN-γ (XMG1.2), PEcy7-IL-4 (BVD6-24G2), PerCPcy5.5-Rat IgG1k isotype control (eBRG1), and PEcy7-Rat IgG1k isotype control (eBRG1 BMDC Preparation and Antigen Presentation Assay. BMDCs were derived using a standard method (31) . Briefly, bone marrow cells were isolated from femur and tibia in complete RPMI-1640 medium, containing 10% (vol/vol) of FBS (HyClone), penicillin (50 U/mL), streptomycin (50 μg/mL), 50 ng/mL of recombinant mGM-CSF (R&D), and 25 ng/mL of recombinant mIL-4 (R&D) in RPMI-1640 (Cellgro) and cultured for 7 d in a humidified 5% (vol/vol) CO 2 incubator at 37°C. Bacterial lipopolysaccharide (LPS; Sigma) was added at 1 μg/mL in the last 16 h for DC maturation. The resulting BMDCs (>90% CD11c + ) were cultured with DN32.D3 or DN3A4-1.2 in the presence or absence of α−GalCer or Gal (α-1→2)α-GalCer [100 ng/mL, generously provided by Gurdyal S. Besra (University of Birmingham, Birmingham, United Kingdom)] and Michael Brenner (Harvard Medical School, Boston, MA) and anti-mCD1d (1B1) or anti-hCD1d (CD1d51) for 24 h. For fixation of BMDC for antigen presentation, 4% (vol/vol) of paraformaldehyde was used to fix the BMDCs at room temperature for 15 min before incubating of BMDCs with lipids and NKT cell hybridomas.
In Vivo Immunization. Mice were immunized i.v. with 2 μg of α-GalCer or vehicle. Their thymus, spleen, and liver were collected at various time points after injection for analyses. For BMDC-mediated lipid delivery, on day 6 of the BMDC preparation, cells were pulsed with α-GalCer (100 ng/mL) or vehicle (0.025% of polysolvate 20) at 37°C in a 5% (vol/vol) CO 2 incubator for 40 h, and 1 μg/mL of LPS was added for the final 16 h. After washing extensively, 1-3 × 10 6 nonadherent cells were i.v. injected to recipient mice as vehicle-BMDC or α-GalCer-pulsed BMDCs 1 d before the administration of B16 melanoma cells.
Determination of Melanoma Lung Metastases. The development of melanoma lung metastases was initiated by an i.v. injection with syngeneic B16 melanoma cells. After 2 wk, recipient mice were killed, their lungs were removed, and the numbers of metastatic nodules were counted under Omano OM4724 microscope in 20× magnification.
Statistical Analysis. Descriptive statistics are expressed as the mean ± SD values. Comparisons between groups were performed using two-tailed Student t test and a P value of <0.05 was considered significant.
